GenomeNet

Database: UniProt
Entry: Q14966
LinkDB: Q14966
Original site: Q14966 
ID   ZN638_HUMAN             Reviewed;        1978 AA.
AC   Q14966; A0A096LPH6; B5MDV1; B7ZLD1; Q53R34; Q5XJ05; Q68DP3; Q6P2H2; Q7Z3T7;
AC   Q8NF92; Q8TCA1; Q9H2G1; Q9NP37;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2005, sequence version 2.
DT   24-JAN-2024, entry version 191.
DE   RecName: Full=Zinc finger protein 638;
DE   AltName: Full=Cutaneous T-cell lymphoma-associated antigen se33-1 {ECO:0000303|PubMed:11149944};
DE            Short=CTCL-associated antigen se33-1 {ECO:0000303|PubMed:11149944};
DE   AltName: Full=Nuclear protein 220 {ECO:0000303|PubMed:8647861};
DE   AltName: Full=Zinc finger matrin-like protein;
GN   Name=ZNF638; Synonyms=NP220 {ECO:0000303|PubMed:8647861}, ZFML;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), DNA-BINDING, SUBCELLULAR LOCATION,
RP   AND FUNCTION.
RC   TISSUE=Epithelium;
RX   PubMed=8647861; DOI=10.1074/jbc.271.21.12525;
RA   Inagaki H., Matsushima Y., Nakamura K., Ohshima M., Kadowaki T.,
RA   Kitagawa Y.;
RT   "A large DNA-binding nuclear protein with RNA recognition motif and
RT   serine/arginine-rich domain.";
RL   J. Biol. Chem. 271:12525-12531(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), IDENTIFICATION AS TUMOR-ASSOCIATED
RP   ANTIGEN, AND VARIANTS SER-980 AND VAL-1912.
RC   TISSUE=Testis;
RX   PubMed=11149944; DOI=10.1073/pnas.98.2.629;
RA   Eichmueller S., Usener D., Dummer R., Stein A., Thiel D., Schadendorf D.;
RT   "Serological detection of cutaneous T-cell lymphoma-associated antigens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:629-634(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Testis;
RA   Chan C.W., Tsui S.K.W., Fung K.P., Lee C.Y., Waye M.M.Y.;
RT   "Identification of a variant splice form of human nuclear protein NP220
RT   mRNA encoding an isoform with truncated carboxyl-terminal.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS VAL-110
RP   AND MET-1726.
RC   TISSUE=Cervix, and Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Cerebellum, Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH FHL2.
RX   PubMed=11813260; DOI=10.1002/jcb.10041.abs;
RA   Ng E.K.O., Chan K.K., Wong C.H., Tsui S.K.W., Ngai S.M., Lee S.M.Y.,
RA   Kotaka M., Lee C.Y., Waye M.M.Y., Fung K.P.;
RT   "Interaction of the heart-specific LIM domain protein, FHL2, with DNA-
RT   binding nuclear protein, hNP220.";
RL   J. Cell. Biochem. 84:556-566(2002).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-552, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-605, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128; SER-383; SER-420;
RP   SER-614; SER-1401 AND SER-1882, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128 AND SER-1100, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128; SER-383; SER-552 AND
RP   SER-1667, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1401, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128; SER-289; SER-299;
RP   SER-369; SER-383; SER-420; SER-552; SER-605; SER-636; SER-1100; SER-1667
RP   AND SER-1882, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-605, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-47; ARG-49 AND ARG-54, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [22]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-292; LYS-775; LYS-1676 AND
RP   LYS-1820, SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-913 (ISOFORM 6), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [23]
RP   FUNCTION, DNA-BINDING, AND INTERACTION WITH MPHOSPH8; TASOR; SETDB1; HDAC1
RP   AND HDAC4.
RX   PubMed=30487602; DOI=10.1038/s41586-018-0750-6;
RA   Zhu Y., Wang G.Z., Cingoez O., Goff S.P.;
RT   "NP220 mediates silencing of unintegrated retroviral DNA.";
RL   Nature 564:278-282(2018).
CC   -!- FUNCTION: Transcription factor that binds to cytidine clusters in
CC       double-stranded DNA (PubMed:8647861, PubMed:30487602). Plays a key role
CC       in the silencing of unintegrated retroviral DNA: some part of the
CC       retroviral DNA formed immediately after infection remains unintegrated
CC       in the host genome and is transcriptionally repressed
CC       (PubMed:30487602). Mediates transcriptional repression of unintegrated
CC       viral DNA by specifically binding to the cytidine clusters of
CC       retroviral DNA and mediating the recruitment of chromatin silencers,
CC       such as the HUSH complex, SETDB1 and the histone deacetylases HDAC1 and
CC       HDAC4 (PubMed:30487602). Acts as an early regulator of adipogenesis by
CC       acting as a transcription cofactor of CEBPs (CEBPA, CEBPD and/or
CC       CEBPG), controlling the expression of PPARG and probably of other
CC       proadipogenic genes, such as SREBF1 (By similarity). May also regulate
CC       alternative splicing of target genes during adipogenesis (By
CC       similarity). {ECO:0000250|UniProtKB:Q61464,
CC       ECO:0000269|PubMed:30487602, ECO:0000269|PubMed:8647861}.
CC   -!- SUBUNIT: Interacts with FHL2 (PubMed:11813260). Interacts with CEBPA,
CC       CEBPD and CEBPG (By similarity). Interacts with MPHOSPH8 and TASOR
CC       components of the HUSH complex; leading to recruitment of the HUSH
CC       complex (PubMed:30487602). Interacts with SETDB1 (PubMed:30487602).
CC       Interacts with HDAC1 (PubMed:30487602). Interacts with HDAC4
CC       (PubMed:30487602). {ECO:0000250|UniProtKB:Q61464,
CC       ECO:0000269|PubMed:11813260, ECO:0000269|PubMed:30487602}.
CC   -!- INTERACTION:
CC       Q14966-2; P50570-2: DNM2; NbExp=3; IntAct=EBI-25845021, EBI-10968534;
CC       Q14966-2; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-25845021, EBI-11110431;
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000255|PROSITE-
CC       ProRule:PRU00130, ECO:0000269|PubMed:11813260,
CC       ECO:0000269|PubMed:8647861}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=Q14966-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14966-2; Sequence=VSP_014802, VSP_014803;
CC       Name=3;
CC         IsoId=Q14966-3; Sequence=VSP_014806;
CC       Name=4;
CC         IsoId=Q14966-4; Sequence=VSP_014804, VSP_014805;
CC       Name=5;
CC         IsoId=Q14966-5; Sequence=VSP_014801;
CC       Name=6;
CC         IsoId=Q14966-6; Sequence=VSP_059342, VSP_059343;
CC   -!- DOMAIN: The matrin-type zinc finger domain is required for localization
CC       to nuclear speckles. {ECO:0000250|UniProtKB:Q61464}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Tumor-associated antigen found in several
CC       cutaneous T-cell lymphoma (CTCL), and in particular in mycosis
CC       fungoides patients and in Sezary syndrome patients.
CC       {ECO:0000305|PubMed:11149944}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Broadly expressed. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH64530.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D83032; BAA11748.1; -; mRNA.
DR   EMBL; AF273049; AAG34909.1; -; mRNA.
DR   EMBL; AF534078; AAM97681.1; -; mRNA.
DR   EMBL; BX537425; CAD97667.1; -; mRNA.
DR   EMBL; CR749322; CAH18177.1; -; mRNA.
DR   EMBL; AC007878; AAF66079.1; -; Genomic_DNA.
DR   EMBL; AC096569; AAY14979.1; -; Genomic_DNA.
DR   EMBL; AC104084; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC109343; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC024000; AAH24000.1; -; mRNA.
DR   EMBL; BC064530; AAH64530.1; ALT_SEQ; mRNA.
DR   EMBL; BC083513; AAH83513.1; -; mRNA.
DR   EMBL; BC143728; AAI43729.1; -; mRNA.
DR   CCDS; CCDS1917.1; -. [Q14966-1]
DR   PIR; JU0239; JU0239.
DR   PIR; JU0240; JU0240.
DR   RefSeq; NP_001014972.1; NM_001014972.2. [Q14966-1]
DR   RefSeq; NP_001239541.1; NM_001252612.1. [Q14966-1]
DR   RefSeq; NP_001239542.1; NM_001252613.1. [Q14966-3]
DR   RefSeq; NP_055312.2; NM_014497.4. [Q14966-1]
DR   PDB; 6SXW; X-ray; 2.75 A; A=676-749.
DR   PDBsum; 6SXW; -.
DR   AlphaFoldDB; Q14966; -.
DR   SMR; Q14966; -.
DR   BioGRID; 118145; 280.
DR   DIP; DIP-42386N; -.
DR   IntAct; Q14966; 71.
DR   MINT; Q14966; -.
DR   STRING; 9606.ENSP00000386433; -.
DR   GlyGen; Q14966; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q14966; -.
DR   PhosphoSitePlus; Q14966; -.
DR   SwissPalm; Q14966; -.
DR   BioMuta; ZNF638; -.
DR   DMDM; 71153483; -.
DR   CPTAC; CPTAC-1371; -.
DR   EPD; Q14966; -.
DR   jPOST; Q14966; -.
DR   MassIVE; Q14966; -.
DR   MaxQB; Q14966; -.
DR   PaxDb; 9606-ENSP00000386433; -.
DR   PeptideAtlas; Q14966; -.
DR   ProteomicsDB; 60262; -. [Q14966-1]
DR   ProteomicsDB; 60263; -. [Q14966-2]
DR   ProteomicsDB; 60264; -. [Q14966-3]
DR   ProteomicsDB; 60265; -. [Q14966-4]
DR   ProteomicsDB; 60266; -. [Q14966-5]
DR   Pumba; Q14966; -.
DR   Antibodypedia; 31207; 130 antibodies from 22 providers.
DR   DNASU; 27332; -.
DR   Ensembl; ENST00000264447.9; ENSP00000264447.4; ENSG00000075292.19. [Q14966-1]
DR   Ensembl; ENST00000409544.5; ENSP00000386433.1; ENSG00000075292.19. [Q14966-1]
DR   Ensembl; ENST00000410075.5; ENSP00000485608.1; ENSG00000075292.19. [Q14966-6]
DR   GeneID; 27332; -.
DR   KEGG; hsa:27332; -.
DR   MANE-Select; ENST00000264447.9; ENSP00000264447.4; NM_014497.5; NP_055312.2.
DR   UCSC; uc002shx.4; human. [Q14966-1]
DR   AGR; HGNC:17894; -.
DR   CTD; 27332; -.
DR   DisGeNET; 27332; -.
DR   GeneCards; ZNF638; -.
DR   HGNC; HGNC:17894; ZNF638.
DR   HPA; ENSG00000075292; Low tissue specificity.
DR   MIM; 614349; gene.
DR   neXtProt; NX_Q14966; -.
DR   OpenTargets; ENSG00000075292; -.
DR   PharmGKB; PA134983478; -.
DR   VEuPathDB; HostDB:ENSG00000075292; -.
DR   eggNOG; ENOG502QVQ7; Eukaryota.
DR   GeneTree; ENSGT00940000153322; -.
DR   HOGENOM; CLU_002180_0_0_1; -.
DR   InParanoid; Q14966; -.
DR   OMA; DEPHMSA; -.
DR   OrthoDB; 5362494at2759; -.
DR   PhylomeDB; Q14966; -.
DR   TreeFam; TF333921; -.
DR   PathwayCommons; Q14966; -.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   SignaLink; Q14966; -.
DR   BioGRID-ORCS; 27332; 61 hits in 1160 CRISPR screens.
DR   ChiTaRS; ZNF638; human.
DR   GeneWiki; ZNF638; -.
DR   GenomeRNAi; 27332; -.
DR   Pharos; Q14966; Tbio.
DR   PRO; PR:Q14966; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q14966; Protein.
DR   Bgee; ENSG00000075292; Expressed in calcaneal tendon and 209 other cell types or tissues.
DR   ExpressionAtlas; Q14966; baseline and differential.
DR   Genevisible; Q14966; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0003690; F:double-stranded DNA binding; TAS:ProtInc.
DR   GO; GO:0003729; F:mRNA binding; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0043484; P:regulation of RNA splicing; IBA:GO_Central.
DR   GO; GO:0008380; P:RNA splicing; TAS:ProtInc.
DR   CDD; cd12716; RRM1_2_NP220; 1.
DR   Gene3D; 3.30.70.330; -; 3.
DR   Gene3D; 3.30.160.60; Classic Zinc Finger; 1.
DR   InterPro; IPR000690; Matrin/U1-C_Znf_C2H2.
DR   InterPro; IPR003604; Matrin/U1-like-C_Znf_C2H2.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR033096; ZNF638_RRM1/2.
DR   InterPro; IPR022755; Znf_C2H2_jaz.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR15592; MATRIN 3/NUCLEAR PROTEIN 220-RELATED; 1.
DR   PANTHER; PTHR15592:SF1; ZINC FINGER PROTEIN 638; 1.
DR   Pfam; PF00076; RRM_1; 1.
DR   Pfam; PF12171; zf-C2H2_jaz; 1.
DR   SMART; SM00360; RRM; 2.
DR   SMART; SM00355; ZnF_C2H2; 2.
DR   SMART; SM00451; ZnF_U1; 2.
DR   SUPFAM; SSF57667; beta-beta-alpha zinc fingers; 1.
DR   SUPFAM; SSF54928; RNA-binding domain, RBD; 3.
DR   PROSITE; PS50102; RRM; 1.
DR   PROSITE; PS50171; ZF_MATRIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; DNA-binding;
KW   Isopeptide bond; Metal-binding; Methylation; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN           1..1978
FT                   /note="Zinc finger protein 638"
FT                   /id="PRO_0000082011"
FT   DOMAIN          676..751
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          905..979
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DNA_BIND        1353..1477
FT                   /evidence="ECO:0000269|PubMed:8647861"
FT   ZN_FING         1928..1958
FT                   /note="Matrin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00130"
FT   REGION          1..48
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          465..638
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          472..571
FT                   /note="Involved in localization to nuclear speckles"
FT                   /evidence="ECO:0000250|UniProtKB:Q61464"
FT   REGION          835..861
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1094..1148
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1294..1340
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1354..1532
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1793..1823
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1867..1916
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1946..1978
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        472..489
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        490..543
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        560..583
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        589..605
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        607..637
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        838..852
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1107..1142
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1370..1396
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1404..1421
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1446..1469
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1481..1509
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1793..1819
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1878..1907
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         47
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         49
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         54
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         128
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         289
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         299
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         369
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         383
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         420
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         552
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         605
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         614
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         636
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1401
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         1641
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61464"
FT   MOD_RES         1667
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1882
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        292
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        775
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1676
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1820
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..903
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11149944"
FT                   /id="VSP_014801"
FT   VAR_SEQ         793..918
FT                   /note="AKTGQAKASVAKVNKSTGKSASSVKSVVTVAVKGNKASIKTAKSGGKKSLEA
FT                   KKTGNVKNKDSNKPVTIPENSEIKTSIEVKATENCAKEAISDAALEATENEPLNKETEE
FT                   MCVMLVSNLPNKGYS -> ESVDQTQQLVPLVRNTARDHDGTPENEGEETVQSALFGFQ
FT                   YDASDHTMAWLGPNTVPEVKEMILQDPQLQTTQLPQTTQAPDITWGMLKKTTYKAEQIL
FT                   LQTQKPFTPDNLFLALLSGDAKPEYEQ (in isoform 6)"
FT                   /id="VSP_059342"
FT   VAR_SEQ         793..814
FT                   /note="AKTGQAKASVAKVNKSTGKSAS -> GLLPTGGGNNYPQIVLAPGLCH (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014802"
FT   VAR_SEQ         815..1978
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014803"
FT   VAR_SEQ         919..1978
FT                   /note="Missing (in isoform 6)"
FT                   /id="VSP_059343"
FT   VAR_SEQ         1100..1139
FT                   /note="SPGLKNSPIDESEVQTATDSPSVKPNELEEESTPSIQTET -> RLWLSKTL
FT                   RILKALLVEVPNLKRSHYFHLIWMNLLLWMRL (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_014804"
FT   VAR_SEQ         1140..1978
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_014805"
FT   VAR_SEQ         1918..1938
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_014806"
FT   VARIANT         110
FT                   /note="I -> V (in dbSNP:rs12612365)"
FT                   /evidence="ECO:0000269|PubMed:17974005"
FT                   /id="VAR_023069"
FT   VARIANT         980
FT                   /note="N -> S (in dbSNP:rs3732235)"
FT                   /evidence="ECO:0000269|PubMed:11149944"
FT                   /id="VAR_023070"
FT   VARIANT         1462
FT                   /note="S -> N (in dbSNP:rs10427371)"
FT                   /id="VAR_052238"
FT   VARIANT         1726
FT                   /note="V -> M (in dbSNP:rs1804020)"
FT                   /evidence="ECO:0000269|PubMed:17974005"
FT                   /id="VAR_023071"
FT   VARIANT         1912
FT                   /note="A -> V (in dbSNP:rs11542286)"
FT                   /evidence="ECO:0000269|PubMed:11149944"
FT                   /id="VAR_023072"
FT   CONFLICT        58
FT                   /note="H -> L (in Ref. 1; BAA11748)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        209
FT                   /note="I -> V (in Ref. 3; AAM97681)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        262
FT                   /note="M -> I (in Ref. 4; CAD97667)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        599
FT                   /note="A -> V (in Ref. 4; CAH18177)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        801
FT                   /note="S -> C (in Ref. 1; BAA11748)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        977
FT                   /note="A -> D (in Ref. 4; CAD97667)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1205
FT                   /note="F -> L (in Ref. 4; CAD97667)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1243
FT                   /note="S -> P (in Ref. 4; CAD97667)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1336
FT                   /note="G -> S (in Ref. 4; CAH18177)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1404
FT                   /note="A -> T (in Ref. 4; CAD97667)"
FT                   /evidence="ECO:0000305"
FT   STRAND          677..682
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   HELIX           690..697
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   HELIX           698..700
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   STRAND          703..709
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   HELIX           710..712
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   STRAND          714..722
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   HELIX           723..732
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   STRAND          745..747
FT                   /evidence="ECO:0007829|PDB:6SXW"
FT   CROSSLNK        Q14966-6:913
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
SQ   SEQUENCE   1978 AA;  220625 MW;  FC006A4BA4885455 CRC64;
     MSRPRFNPRG DFPLQRPRAP NPSGMRPPGP FMRPGSMGLP RFYPAGRARG IPHRFAGHES
     YQNMGPQRMN VQVTQHRTDP RLTKEKLDFH EAQQKKGKPH GSRWDDEPHI SASVAVKQSS
     VTQVTEQSPK VQSRYTKESA SSILASFGLS NEDLEELSRY PDEQLTPENM PLILRDIRMR
     KMGRRLPNLP SQSRNKETLG SEAVSSNVID YGHASKYGYT EDPLEVRIYD PEIPTDEVEN
     EFQSQQNISA SVPNPNVICN SMFPVEDVFR QMDFPGESSN NRSFFSVESG TKMSGLHISG
     GQSVLEPIKS VNQSINQTVS QTMSQSLIPP SMNQQPFSSE LISSVSQQER IPHEPVINSS
     NVHVGSRGSK KNYQSQADIP IRSPFGIVKA SWLPKFSHAD AQKMKRLPTP SMMNDYYAAS
     PRIFPHLCSL CNVECSHLKD WIQHQNTSTH IESCRQLRQQ YPDWNPEILP SRRNEGNRKE
     NETPRRRSHS PSPRRSRRSS SSHRFRRSRS PMHYMYRPRS RSPRICHRFI SRYRSRSRSR
     SPYRIRNPFR GSPKCFRSVS PERMSRRSVR SSDRKKALED VVQRSGHGTE FNKQKHLEAA
     DKGHSPAQKP KTSSGTKPSV KPTSATKSDS NLGGHSIRCK SKNLEDDTLS ECKQVSDKAV
     SLQRKLRKEQ SLHYGSVLLI TELPEDGCTE EDVRKLFQPF GKVNDVLIVP YRKEAYLEME
     FKEAITAIMK YIETTPLTIK GKSVKICVPG KKKAQNKEVK KKTLESKKVS ASTLKRDADA
     SKAVEIVTST SAAKTGQAKA SVAKVNKSTG KSASSVKSVV TVAVKGNKAS IKTAKSGGKK
     SLEAKKTGNV KNKDSNKPVT IPENSEIKTS IEVKATENCA KEAISDAALE ATENEPLNKE
     TEEMCVMLVS NLPNKGYSVE EVYDLAKPFG GLKDILILSS HKKAYIEINR KAAESMVKFY
     TCFPVLMDGN QLSISMAPEN MNIKDEEAIF ITLVKENDPE ANIDTIYDRF VHLDNLPEDG
     LQCVLCVGLQ FGKVDHHVFI SNRNKAILQL DSPESAQSMY SFLKQNPQNI GDHMLTCSLS
     PKIDLPEVQI EHDPELEKES PGLKNSPIDE SEVQTATDSP SVKPNELEEE STPSIQTETL
     VQQEEPCEEE AEKATCDSDF AVETLELETQ GEEVKEEIPL VASASVSIEQ FTENAEECAL
     NQQMFNSDLE KKGAEIINPK TALLPSDSVF AEERNLKGIL EESPSEAEDF ISGITQTMVE
     AVAEVEKNET VSEILPSTCI VTLVPGIPTG DEKTVDKKNI SEKKGNMDEK EEKEFNTKET
     RMDLQIGTEK AEKNEGRMDA EKVEKMAAMK EKPAENTLFK AYPNKGVGQA NKPDETSKTS
     ILAVSDVSSS KPSIKAVIVS SPKAKATVSK TENQKSFPKS VPRDQINAEK KLSAKEFGLL
     KPTSARSGLA ESSSKFKPTQ SSLTRGGSGR ISALQGKLSK LDYRDITKQS QETEARPSIM
     KRDDSNNKTL AEQNTKNPKS TTGRSSKSKE EPLFPFNLDE FVTVDEVIEE VNPSQAKQNP
     LKGKRKETLK NVPFSELNLK KKKGKTSTPR GVEGELSFVT LDEIGEEEDA AAHLAQALVT
     VDEVIDEEEL NMEEMVKNSN SLFTLDELID QDDCISHSEP KDVTVLSVAE EQDLLKQERL
     VTVDEIGEVE ELPLNESADI TFATLNTKGN EGDTVRDSIG FISSQVPEDP STLVTVDEIQ
     DDSSDLHLVT LDEVTEEDED SLADFNNLKE ELNFVTVDEV GEEEDGDNDL KVELAQSKND
     HPTDKKGNRK KRAVDTKKTK LESLSQVGPV NENVMEEDLK TMIERHLTAK TPTKRVRIGK
     TLPSEKAVVT EPAKGEEAFQ MSEVDEESGL KDSEPERKRK KTEDSSSGKS VASDVPEELD
     FLVPKAGFFC PICSLFYSGE KAMTNHCKST RHKQNTEKFM AKQRKEKEQN EAEERSSR
//
DBGET integrated database retrieval system